Skip to main content
PMC home page
The American Journal of Pathology logoLink to The American Journal of Pathology
. 1995 Dec;147(6):1615–1625.

Diagnostic assessment of two novel proliferation-specific antigens in benign and malignant melanocytic lesions.

P Rudolph 1, T Lappe 1, C Schubert 1, D Schmidt 1, R M Parwaresch 1, E Christophers 1
PMCID: PMC1869947  PMID: 7495287

Abstract

The aim of this study was to gain a thorough insight into the proliferative activity of benign and malignant melanocytic tumors. A total of 314 cases were examined by immunohistochemistry on paraffin-embedded material. The growth fraction was assessed by means of two monoclonal antibodies, Ki-S1 and Ki-S5, which react with two different proliferation-specific nuclear antigens. Additionally, HMB-45 was used as a marker of melanocytic activation. Statistically significant differences (P < 0.01) in the proliferation rates were found between common acquired nevi, Spitz's/Reed's nevi, primary cutaneous melanomas, and metastatic melanomas, whereas dysplastic nevi were hardly distinct from other nevi of the compound type. In melanoma, the growth fraction correlated well with the tumor stage but poorly with HMB-45 expression and mitotic count. Along with tumor progression, an increasing heterogeneity of proliferation indices was observed. Our results provide no evidence for a progression from dysplastic nevi into melanoma. They indicate that the assessment of the proliferative activity may be of considerable diagnostic help in cases of uncertain histology and that it might contribute to an alternative concept for the classification of melanocytic tumors.

Full text

PDF
1617

Images in this article

1619Figure 1
on p.1619
1620Figure 2
on p.1620

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ackerman A. B., Borghi S. "Pagetoid melanocytic proliferation" is the latest evasion from a diagnosis of "melanoma in situ". Am J Dermatopathol. 1991 Dec;13(6):583–604. doi: 10.1097/00000372-199113060-00010. [DOI] [PubMed] [Google Scholar]
  2. Ackerman A. B. Macular and patch lesions of malignant melanoma: malignant melanoma in situ. J Dermatol Surg Oncol. 1983 Aug;9(8):615–618. doi: 10.1111/j.1524-4725.1983.tb00868.x. [DOI] [PubMed] [Google Scholar]
  3. Ackerman A. B., Mihara I. Dysplasia, dysplastic melanocytes, dysplastic nevi, the dysplastic nevus syndrome, and the relation between dysplastic nevi and malignant melanomas. Hum Pathol. 1985 Jan;16(1):87–91. [PubMed] [Google Scholar]
  4. Ackerman A. B., Milde P. Naming acquired melanocytic nevi. Common and dysplastic, normal and atypical, or Unna, Miescher, Spitz, and Clark? Am J Dermatopathol. 1992 Oct;14(5):447–453. doi: 10.1097/00000372-199210000-00013. [DOI] [PubMed] [Google Scholar]
  5. Ackerman A. B. What naevus is dysplastic, a syndrome and the commonest precursor of malignant melanoma? A riddle and an answer. Histopathology. 1988 Sep;13(3):241–256. doi: 10.1111/j.1365-2559.1988.tb02036.x. [DOI] [PubMed] [Google Scholar]
  6. Baak J. P. Mitosis counting in tumors. Hum Pathol. 1990 Jul;21(7):683–685. doi: 10.1016/0046-8177(90)90026-2. [DOI] [PubMed] [Google Scholar]
  7. Bale S. J., Dracopoli N. C., Tucker M. A., Clark W. H., Jr, Fraser M. C., Stanger B. Z., Green P., Donis-Keller H., Housman D. E., Greene M. H. Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus to chromosome 1p. N Engl J Med. 1989 May 25;320(21):1367–1372. doi: 10.1056/NEJM198905253202102. [DOI] [PubMed] [Google Scholar]
  8. Ballard D. W., Kranz D. M., Voss E. W., Jr Monoclonal IgM antibody exhibiting high-affinity binding and cryoglobulin properties. Proc Natl Acad Sci U S A. 1983 Aug;80(16):5071–5074. doi: 10.1073/pnas.80.16.5071. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Barnhill R. L., Levy M. A. Regressing thin cutaneous malignant melanomas (< or = 1.0 mm) are associated with angiogenesis. Am J Pathol. 1993 Jul;143(1):99–104. [PMC free article] [PubMed] [Google Scholar]
  10. Bergman W., Ruiter D. J., Scheffer E., van Vloten W. A. Melanocytic atypia in dysplastic nevi. Immunohistochemical and cytophotometrical analysis. Cancer. 1988 Apr 15;61(8):1660–1666. doi: 10.1002/1097-0142(19880415)61:8<1660::aid-cncr2820610825>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  11. Bosch F. X., Udvarhelyi N., Venter E., Herold-Mende C., Schuhmann A., Maier H., Weidauer H., Born A. I. Expression of the histone H3 gene in benign, semi-malignant and malignant lesions of the head and neck: a reliable proliferation marker. Eur J Cancer. 1993;29A(10):1454–1461. doi: 10.1016/0959-8049(93)90020-g. [DOI] [PubMed] [Google Scholar]
  12. Camplejohn R. S., Brock A., Barnes D. M., Gillett C., Raikundalia B., Kreipe H., Parwaresch M. R. Ki-S1, a novel proliferative marker: flow cytometric assessment of staining in human breast carcinoma cells. Br J Cancer. 1993 Apr;67(4):657–662. doi: 10.1038/bjc.1993.122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Celis J. E., Madsen P. Increased nuclear cyclin/PCNA antigen staining of non S-phase transformed human amnion cells engaged in nucleotide excision DNA repair. FEBS Lett. 1986 Dec 15;209(2):277–283. doi: 10.1016/0014-5793(86)81127-9. [DOI] [PubMed] [Google Scholar]
  14. Clark W. H., Jr, Elder D. E., Guerry D., 4th, Epstein M. N., Greene M. H., Van Horn M. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol. 1984 Dec;15(12):1147–1165. doi: 10.1016/s0046-8177(84)80310-x. [DOI] [PubMed] [Google Scholar]
  15. Clark W. H., Jr, Evans H. L., Everett M. A., Farmer E. R., Graham J. H., Mihm M. C., Jr, Rosai J., Sagebiel R. W., Wick M. R. Early melanoma. Histologic terms. Am J Dermatopathol. 1991 Dec;13(6):579–582. [PubMed] [Google Scholar]
  16. Clark W. H., Jr Malignant melanoma in situ. Hum Pathol. 1990 Dec;21(12):1197–1198. doi: 10.1016/s0046-8177(06)80029-8. [DOI] [PubMed] [Google Scholar]
  17. Clark W. H., Jr, Reimer R. R., Greene M., Ainsworth A. M., Mastrangelo M. J. Origin of familial malignant melanomas from heritable melanocytic lesions. 'The B-K mole syndrome'. Arch Dermatol. 1978 May;114(5):732–738. [PubMed] [Google Scholar]
  18. Clemente C., Cochran A. J., Elder D. E., Levene A., MacKie R. M., Mihm M. C., Rilke F., Cascinelli N., Fitzpatrick T. B., Sober A. J. Histopathologic diagnosis of dysplastic nevi: concordance among pathologists convened by the World Health Organization Melanoma Programme. Hum Pathol. 1991 Apr;22(4):313–319. doi: 10.1016/0046-8177(91)90078-4. [DOI] [PubMed] [Google Scholar]
  19. Cochran A. J., Bailly C., Paul E., Dolbeau D. Nevi, other than dysplastic and Spitz nevi. Semin Diagn Pathol. 1993 Feb;10(1):3–17. [PubMed] [Google Scholar]
  20. Crucioli V., Stilwell J. The histogenesis of malignant melanoma in relation to pre-existing pigmented lesions. J Cutan Pathol. 1982 Dec;9(6):396–404. doi: 10.1111/j.1600-0560.1982.tb01078.x. [DOI] [PubMed] [Google Scholar]
  21. Di Gregorio C., Losi L., Annessi G., Botticelli A. Nucleolar organizer regions in malignant melanoma and melanocytic nevi. Comparison of two counting methods. Am J Dermatopathol. 1991 Aug;13(4):329–333. doi: 10.1097/00000372-199108000-00002. [DOI] [PubMed] [Google Scholar]
  22. Duncan E. L., Whitaker N. J., Moy E. L., Reddel R. R. Assignment of SV40-immortalized cells to more than one complementation group for immortalization. Exp Cell Res. 1993 Apr;205(2):337–344. doi: 10.1006/excr.1993.1095. [DOI] [PubMed] [Google Scholar]
  23. Duncan L. M., Berwick M., Bruijn J. A., Byers H. R., Mihm M. C., Barnhill R. L. Histopathologic recognition and grading of dysplastic melanocytic nevi: an interobserver agreement study. J Invest Dermatol. 1993 Mar;100(3):318S–321S. doi: 10.1111/1523-1747.ep12470215. [DOI] [PubMed] [Google Scholar]
  24. Elder D. E., Goldman L. I., Goldman S. C., Greene M. H., Clark W. H., Jr Dysplastic nevus syndrome: a phenotypic association of sporadic cutaneous melanoma. Cancer. 1980 Oct 15;46(8):1787–1794. doi: 10.1002/1097-0142(19801015)46:8<1787::aid-cncr2820460816>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  25. Elder D. E., Rodeck U., Thurin J., Cardillo F., Clark W. H., Stewart R., Herlyn M. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas. Cancer Res. 1989 Sep 15;49(18):5091–5096. [PubMed] [Google Scholar]
  26. Elder D. E. The dysplastic nevus. Pathology. 1985 Apr;17(2):291–297. doi: 10.3109/00313028509063770. [DOI] [PubMed] [Google Scholar]
  27. Fleming M. G., Friedman R. J. Multiparametric image cytometry of nevi and melanomas. Am J Dermatopathol. 1993 Apr;15(2):106–113. doi: 10.1097/00000372-199304000-00002. [DOI] [PubMed] [Google Scholar]
  28. Flotte T. J. Malignant melanoma in situ. Hum Pathol. 1990 Dec;21(12):1199–1201. doi: 10.1016/s0046-8177(06)80030-4. [DOI] [PubMed] [Google Scholar]
  29. Gerdes J., Lemke H., Baisch H., Wacker H. H., Schwab U., Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984 Oct;133(4):1710–1715. [PubMed] [Google Scholar]
  30. Gerdes J., Li L., Schlueter C., Duchrow M., Wohlenberg C., Gerlach C., Stahmer I., Kloth S., Brandt E., Flad H. D. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol. 1991 Apr;138(4):867–873. [PMC free article] [PubMed] [Google Scholar]
  31. Green M. S., Ackerman A. B. Thickness is not an accurate gauge of prognosis of primary cutaneous melanoma. Am J Dermatopathol. 1993 Oct;15(5):461–473. doi: 10.1097/00000372-199310000-00009. [DOI] [PubMed] [Google Scholar]
  32. Greene M. H., Goldin L. R., Clark W. H., Jr, Lovrien E., Kraemer K. H., Tucker M. A., Elder D. E., Fraser M. C., Rowe S. Familial cutaneous malignant melanoma: autosomal dominant trait possibly linked to the Rh locus. Proc Natl Acad Sci U S A. 1983 Oct;80(19):6071–6075. doi: 10.1073/pnas.80.19.6071. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Hall P. A., Levison D. A., Woods A. L., Yu C. C., Kellock D. B., Watkins J. A., Barnes D. M., Gillett C. E., Camplejohn R., Dover R. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol. 1990 Dec;162(4):285–294. doi: 10.1002/path.1711620403. [DOI] [PubMed] [Google Scholar]
  34. Hastrup N., Osterlind A., Drzewiecki K. T., Hou-Jensen K. The presence of dysplastic nevus remnants in malignant melanomas. A population-based study of 551 malignant melanomas. Am J Dermatopathol. 1991 Aug;13(4):378–385. doi: 10.1097/00000372-199108000-00009. [DOI] [PubMed] [Google Scholar]
  35. Jaspers N. G., Roza-de Jongh E. J., Donselaar I. G., Van Velzen-Tillemans J. T., van Hemel J. O., Rümke P., van der Kamp A. W. Sister chromatid exchanges, hyperdiploidy and chromosomal rearrangements studied in cells from melanoma-prone individuals belonging to families with the dysplastic nevus syndrome. Cancer Genet Cytogenet. 1987 Jan;24(1):33–43. doi: 10.1016/0165-4608(87)90081-1. [DOI] [PubMed] [Google Scholar]
  36. Kaudewitz P., Braun-Falco O., Ernst M., Landthaler M., Stolz W., Gerdes J. Tumor cell growth fractions in human malignant melanomas and the correlation to histopathologic tumor grading. Am J Pathol. 1989 May;134(5):1063–1068. [PMC free article] [PubMed] [Google Scholar]
  37. Kelly J. W., Crutcher W. A., Sagebiel R. W. Clinical diagnosis of dysplastic melanocytic nevi. A clinicopathologic correlation. J Am Acad Dermatol. 1986 Jun;14(6):1044–1052. doi: 10.1016/s0190-9622(86)70131-x. [DOI] [PubMed] [Google Scholar]
  38. Klein L. J., Barr R. J. Histologic atypia in clinically benign nevi. A prospective study. J Am Acad Dermatol. 1990 Feb;22(2 Pt 1):275–282. doi: 10.1016/0190-9622(90)70037-i. [DOI] [PubMed] [Google Scholar]
  39. Kreipe H., Alm P., Olsson H., Hauberg M., Fischer L., Parwaresch R. Prognostic significance of a formalin-resistant nuclear proliferation antigen in mammary carcinomas as determined by the monoclonal antibody Ki-S1. Am J Pathol. 1993 Feb;142(2):651–657. [PMC free article] [PubMed] [Google Scholar]
  40. Kreipe H., Wacker H. H., Heidebrecht H. J., Haas K., Hauberg M., Tiemann M., Parwaresch R. Determination of the growth fraction in non-Hodgkin's lymphomas by monoclonal antibody Ki-S5 directed against a formalin-resistant epitope of the Ki-67 antigen. Am J Pathol. 1993 Jun;142(6):1689–1694. [PMC free article] [PubMed] [Google Scholar]
  41. Lindholm C., Bjelkenkrantz K., Hofer P. A. DNA-cytophotometry of benign compound and intradermal naevi, Spitz epithelioid naevi and malignant melanomas. Virchows Arch B Cell Pathol Incl Mol Pathol. 1987;53(4):257–258. doi: 10.1007/BF02890251. [DOI] [PubMed] [Google Scholar]
  42. McCormick D., Hall P. A. The complexities of proliferating cell nuclear antigen. Histopathology. 1992 Dec;21(6):591–594. doi: 10.1111/j.1365-2559.1992.tb00454.x. [DOI] [PubMed] [Google Scholar]
  43. Niemann T. H., Argenyi Z. B. Immunohistochemical study of Spitz nevi and malignant melanoma with use of antibody to proliferating cell nuclear antigen. Am J Dermatopathol. 1993 Oct;15(5):441–445. doi: 10.1097/00000372-199310000-00005. [DOI] [PubMed] [Google Scholar]
  44. Parmiter A. H., Balaban G., Clark W. H., Jr, Nowell P. C. Possible involvement of the chromosome region 10q24----q26 in early stages of melanocytic neoplasia. Cancer Genet Cytogenet. 1988 Feb;30(2):313–317. doi: 10.1016/0165-4608(88)90200-2. [DOI] [PubMed] [Google Scholar]
  45. Piepkorn M., Meyer L. J., Goldgar D., Seuchter S. A., Cannon-Albright L. A., Skolnick M. H., Zone J. J. The dysplastic melanocytic nevus: a prevalent lesion that correlates poorly with clinical phenotype. J Am Acad Dermatol. 1989 Mar;20(3):407–415. doi: 10.1016/s0190-9622(89)70050-5. [DOI] [PubMed] [Google Scholar]
  46. Quinn C. M., Wright N. A. The clinical assessment of proliferation and growth in human tumours: evaluation of methods and applications as prognostic variables. J Pathol. 1990 Feb;160(2):93–102. doi: 10.1002/path.1711600202. [DOI] [PubMed] [Google Scholar]
  47. Rak J. W., St Croix B. D., Kerbel R. S. Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anticancer Drugs. 1995 Feb;6(1):3–18. doi: 10.1097/00001813-199502000-00001. [DOI] [PubMed] [Google Scholar]
  48. Reed R. J. Minimal deviation melanoma. Hum Pathol. 1990 Dec;21(12):1206–1211. doi: 10.1016/s0046-8177(06)80032-8. [DOI] [PubMed] [Google Scholar]
  49. Rhodes A. R., Harrist T. J., Day C. L., Mihm M. C., Jr, Fitzpatrick T. B., Sober A. J. Dysplastic melanocytic nevi in histologic association with 234 primary cutaneous melanomas. J Am Acad Dermatol. 1983 Oct;9(4):563–574. doi: 10.1016/s0190-9622(83)70171-4. [DOI] [PubMed] [Google Scholar]
  50. Richmond A., Balentien E., Thomas H. G., Flaggs G., Barton D. E., Spiess J., Bordoni R., Francke U., Derynck R. Molecular characterization and chromosomal mapping of melanoma growth stimulatory activity, a growth factor structurally related to beta-thromboglobulin. EMBO J. 1988 Jul;7(7):2025–2033. doi: 10.1002/j.1460-2075.1988.tb03042.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Richmond A., Thomas H. G. Melanoma growth stimulatory activity: isolation from human melanoma tumors and characterization of tissue distribution. J Cell Biochem. 1988 Feb;36(2):185–198. doi: 10.1002/jcb.240360209. [DOI] [PubMed] [Google Scholar]
  52. Rigel D. S., Rivers J. K., Kopf A. W., Friedman R. J., Vinokur A. F., Heilman E. R., Levenstein M. Dysplastic nevi. Markers for increased risk for melanoma. Cancer. 1989 Jan 15;63(2):386–389. doi: 10.1002/1097-0142(19890115)63:2<386::aid-cncr2820630231>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  53. Rowley M. J., Cockerell C. J. Reliability of prognostic models in malignant melanoma. A 10-year follow-up study. Am J Dermatopathol. 1991 Oct;13(5):431–437. doi: 10.1097/00000372-199110000-00001. [DOI] [PubMed] [Google Scholar]
  54. Sadi M. V., Barrack E. R. Determination of growth fraction in advanced prostate cancer by Ki-67 immunostaining and its relationship to the time to tumor progression after hormonal therapy. Cancer. 1991 Jun 15;67(12):3065–3071. doi: 10.1002/1097-0142(19910615)67:12<3065::aid-cncr2820671222>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  55. Sagebiel R. W. Diagnosis and management of premalignant melanocytic proliferations. Pathology. 1985 Apr;17(2):285–290. doi: 10.3109/00313028509063769. [DOI] [PubMed] [Google Scholar]
  56. Sahin A. A., Ro J., Ro J. Y., Blick M. B., el-Naggar A. K., Ordonez N. G., Fritsche H. A., Smith T. L., Hortobagyi G. N., Ayala A. G. Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Significant correlation with prognosis. Cancer. 1991 Aug 1;68(3):549–557. doi: 10.1002/1097-0142(19910801)68:3<549::aid-cncr2820680318>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  57. Salopek T. G., Jimbow K. Dysplastic melanocytic nevus. Immunohistochemical heterogeneity by melanosomal markers and S-100. Am J Dermatopathol. 1991 Apr;13(2):130–136. doi: 10.1097/00000372-199104000-00005. [DOI] [PubMed] [Google Scholar]
  58. Sampson S. A., Kreipe H., Gillett C. E., Smith P., Chaudary M. A., Khan A., Wicks K., Parwaresch R., Barnes D. M. KiS1--a novel monoclonal antibody which recognizes proliferating cells: evaluation of its relationship to prognosis in mammary carcinoma. J Pathol. 1992 Oct;168(2):179–185. doi: 10.1002/path.1711680205. [DOI] [PubMed] [Google Scholar]
  59. Sanford K. K., Tarone R. E., Parshad R., Tucker M. A., Greene M. H., Jones G. M. Hypersensitivity to G2 chromatid radiation damage in familial dysplastic naevus syndrome. Lancet. 1987 Nov 14;2(8568):1111–1116. doi: 10.1016/s0140-6736(87)91546-7. [DOI] [PubMed] [Google Scholar]
  60. Schwarting R. Little missed markers and Ki-67. Lab Invest. 1993 Jun;68(6):597–599. [PubMed] [Google Scholar]
  61. Shi S. R., Key M. E., Kalra K. L. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem. 1991 Jun;39(6):741–748. doi: 10.1177/39.6.1709656. [DOI] [PubMed] [Google Scholar]
  62. Skelton H. G., 3rd, Smith K. J., Barrett T. L., Lupton G. P., Graham J. H. HMB-45 staining in benign and malignant melanocytic lesions. A reflection of cellular activation. Am J Dermatopathol. 1991 Dec;13(6):543–550. doi: 10.1097/00000372-199113060-00004. [DOI] [PubMed] [Google Scholar]
  63. Smolle J., Hofmann-Wellenhof R., Kerl H. Prognostic significance of proliferation and motility in primary malignant melanoma of the skin. J Cutan Pathol. 1992 Apr;19(2):110–115. doi: 10.1111/j.1600-0560.1992.tb01351.x. [DOI] [PubMed] [Google Scholar]
  64. Smoller B. R., McNutt N. S., Hsu A. HMB-45 staining of dysplastic nevi. Support for a spectrum of progression toward melanoma. Am J Surg Pathol. 1989 Aug;13(8):680–684. doi: 10.1097/00000478-198908000-00006. [DOI] [PubMed] [Google Scholar]
  65. Sørensen F. B., Kristensen I. B., Grymer F., Jakobsen A. DNA level, tumor thickness, and stereological estimates of nuclear volume in stage I cutaneous malignant melanomas. A comparative study with analysis of prognostic impact. Am J Dermatopathol. 1991 Feb;13(1):11–19. doi: 10.1097/00000372-199102000-00004. [DOI] [PubMed] [Google Scholar]
  66. Sørensen F. B., Ottosen P. D. Stereological estimation of nuclear volume in benign and malignant melanocytic lesions of the skin. Inter- and intraobserver variability of malignancy grading. Am J Dermatopathol. 1991 Apr;13(2):99–107. doi: 10.1097/00000372-199104000-00001. [DOI] [PubMed] [Google Scholar]
  67. Tron V. A., Barnhill R. L., Mihm M. C., Jr Malignant melanoma in situ: functional considerations of cancer. Hum Pathol. 1990 Dec;21(12):1202–1205. doi: 10.1016/s0046-8177(06)80031-6. [DOI] [PubMed] [Google Scholar]
  68. Tu P., Miyauchi S., Miki Y. Proliferative activities in Spitz nevus compared with melanocytic nevus and malignant melanoma using expression of PCNA/cyclin and mitotic rate. Am J Dermatopathol. 1993 Aug;15(4):311–314. doi: 10.1097/00000372-199308000-00003. [DOI] [PubMed] [Google Scholar]
  69. Tungekar M. F., Gatter K. C., Dunnill M. S., Mason D. Y. Ki-67 immunostaining and survival in operable lung cancer. Histopathology. 1991 Dec;19(6):545–550. doi: 10.1111/j.1365-2559.1991.tb01503.x. [DOI] [PubMed] [Google Scholar]
  70. Ueda T., Aozasa K., Tsujimoto M., Ohsawa M., Uchida A., Aoki Y., Ono K., Matsumoto K. Prognostic significance of Ki-67 reactivity in soft tissue sarcomas. Cancer. 1989 Apr 15;63(8):1607–1611. doi: 10.1002/1097-0142(19890415)63:8<1607::aid-cncr2820630827>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  71. Wong T. Y., Duncan L. M., Mihm M. C., Jr Melanoma mimicking dermal and Spitz's nevus ("nevoid" melanoma). Semin Surg Oncol. 1993 May-Jun;9(3):188–193. [PubMed] [Google Scholar]
  72. Yadav S., Vossaert K. A., Kopf A. W., Silverman M., Grin-Jorgensen C. Histopathologic correlates of structures seen on dermoscopy (epiluminescence microscopy). Am J Dermatopathol. 1993 Aug;15(4):297–305. doi: 10.1097/00000372-199308000-00001. [DOI] [PubMed] [Google Scholar]
  73. Yamanaka N., Harabuchi Y., Kataura A. The prognostic value of Ki-67 antigen in non-Hodgkin lymphoma of Waldeyer ring and the nasal cavity. Cancer. 1992 Nov 1;70(9):2342–2349. doi: 10.1002/1097-0142(19921101)70:9<2342::aid-cncr2820700922>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  74. de Wit P. E., van't Hof-Grootenboer B., Ruiter D. J., Bondi R., Bröcker E. B., Cesarini J. P., Hastrup N., Hou-Jensen K., MacKie R. M., Scheffer E. Validity of the histopathological criteria used for diagnosing dysplastic naevi. An interobserver study by the pathology subgroup of the EORTC Malignant Melanoma Cooperative Group. Eur J Cancer. 1993;29A(6):831–839. doi: 10.1016/s0959-8049(05)80419-8. [DOI] [PubMed] [Google Scholar]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

RESOURCES